Investor Presentaiton

Rigosertib identified as lead PLK1 inhibitor in RDEB CSCC C A 1600 1400 1200 1000 800 600 Tumor volume (mm³) 400 ** 200 0 Rigosertib Vehicle Tumor 1 * *** *** *** *** *** *** *** *** *** ** 7 8 9 10 11 12 13 14 15 Day Tumor 2 Vehicle Rigosertib Tumor weight (gr) B 2 1.8 1.6 1.41 1.2 1- ** 0.8 0.6 0.4- 0.2 0 Vehicle Rigosertib Tumor 3 Tumor 4 Tumor 5 Tumor 6 Tumor 7 Tumor 8 24 Clin Cancer Res March 7 2019 DOI:10.1158/1078-0432.CCR-18-2661. PMID: 30846478 0 ONCONOVA THERAPEUTICS

View entire presentation